BCLI
BRAINSTORM CELL THERAPEUTICS INC.
$0.7500
-2.60%
No data for this timeframe.
Vol
Inst. Holders10 funds
Inst. Value$88.0K
Inst. Activity1 buys / 0 sells
SEC Reports4
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001137883·Prev Close $0.7700
Recent Activity
Jun 3, 2026
SEC
BrainStorm Cell Therapeutics' S-1 registration statement (File No. 333-296090) was declared effective by the SEC on June
EFFECT — Impact 5/10
May 28, 2026
SEC
Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its Board of Directors, expandin
8-K — Impact 3/10
May 15, 2026
SEC
BrainStorm Cell Therapeutics reported Q1 2026 results with a net loss of $2.1M ($0.19 per share), narrower than the $2.9
8-K — Impact 6/10
Feb 26, 2026
Insider
Lebovits Chaim was granted 1,800,000 shares
President & CEO
Feb 26, 2026
Insider
Yablonka Uri was granted 150,000 shares
EVP & Chief Business Officer
Feb 26, 2026
Insider
Patlis Alla was granted 100,000 shares
See Remarks
Inst.
UBS Group AG — DOUBLED
12,380 shares ($13.9K)
Inst.
UBS Group AG — NEAR_EXIT
253 shares ($319.00)
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 11, 2024 | Maxim Group | UPGRADE | Hold → Buy |
| Sep 28, 2023 | Maxim Group | DOWNGRADE | Buy → Hold |
| Mar 31, 2023 | Maxim Group | MAINTAIN | Buy |
| Feb 5, 2021 | Maxim Group | UPGRADE | Hold → Buy |
| May 15, 2018 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.29 ▼ -20.8% | $-0.29 — $-0.29 | 15% YoY | 1 |
| Next Q | $-0.21 ▼ -10.5% | $-0.21 — $-0.21 | -11% YoY | 1 |
| Current FY | $-1.07 ▲ +29.1% | $-1.07 — $-1.07 | 4% YoY | 1 |
| Next FY | $-0.86 ▲ +16.5% | $-0.86 — $-0.86 | 20% YoY | 1 |
Latest Reports
BEARISH
EFFECT
5/10
BrainStorm Cell Therapeutics' S-1 registration statement (File No. 333-296090) was declared effective by the SEC on June
Jun 3, 2026
NEUTRAL
8-K
3/10
Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its Board of Directors, expandin
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $31.1K | — |
| BlackRock, Inc. | $28.2K | — |
| UBS Group AG | $13.9K | DOUBLED |
| MORGAN STANLEY | $6.5K | — |
| RAYMOND JAMES FINANCIAL INC | $5.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 26, 2026 | Lebovits Chaim | A | $0.00 |
| Feb 26, 2026 | Yablonka Uri | A | $0.00 |
| Feb 26, 2026 | Patlis Alla | A | $0.00 |
| Feb 26, 2026 | FRENKEL JACOB | A | $0.00 |
| Feb 26, 2026 | Bairu Menghisteab | A | $105.0K |
10 institutional holders with $88.0K total value (78,596 shares) as of 2025-Q2. Top holders: VANGUARD, BlackRock,, UBS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q2
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 27,724 | $31.1K | 35.3% | — |
| 2 | BlackRock, Inc. | 25,172 | $28.2K | 32.0% | — |
| 3 | UBS Group AG | 12,380 | $13.9K | 15.8% | DOUBLED +4793.3% |
| 4 | MORGAN STANLEY | 5,803 | $6.5K | 7.4% | — |
| 5 | RAYMOND JAMES FINANCIAL INC | 5,158 | $5.8K | 6.6% | — |
| 6 | WELLS FARGO & COMPANY/MN | 1,338 | $1.5K | 1.7% | — |
| 7 | CITIGROUP INC | 663 | $743.00 | 0.8% | — |
| 8 | JONES FINANCIAL COMPANIES LLLP | 216 | $229.00 | 0.3% | — |
| 9 | BANK OF AMERICA CORP /DE/ | 136 | $152.00 | 0.2% | — |
| 10 | FMR LLC | 6 | $7.00 | 0.0% | DOUBLED +109.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 253 | 12,380 | +4793.3% | $13.9K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 3,472 | 253 | -92.7% | $319.00 | 2025-Q1 |
| FMR LLC | DOUBLED | 111 | 233 | +109.9% | $294.00 | 2025-Q1 |
11 unique insiders with 11 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Lebovits Chaim | President & CEO | AWARD | 1,800,000 | — | — |
| Feb 26, 2026 | Yablonka Uri | EVP & Chief Business Officer | AWARD | 150,000 | — | — |
| Feb 26, 2026 | Patlis Alla | See Remarks | AWARD | 100,000 | — | — |
| Feb 26, 2026 | FRENKEL JACOB A | Director | AWARD | 200,000 | — | — |
| Feb 26, 2026 | Bairu Menghisteab | Director | AWARD | 150,000 | $0.7000 | $105.0K |
| Feb 26, 2026 | Polverino Anthony J. | Director | AWARD | 150,000 | $0.7000 | $105.0K |
| Feb 26, 2026 | HARTOUNIAN HARTOUN | Director | AWARD | 225,000 | $0.7000 | $157.5K |
| Feb 26, 2026 | Dagher Ibrahim B. | Director | AWARD | 225,000 | $0.7000 | $157.5K |
| Feb 26, 2026 | Naor Nir | Director | AWARD | 180,000 | $0.7000 | $126.0K |
| Feb 26, 2026 | Lindborg Stacy | Director | AWARD | 150,000 | $0.7000 | $105.0K |
| Feb 26, 2026 | ARBEL IRIT | Director | AWARD | 120,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BEARISH
EFFECT
5/10
BrainStorm Cell Therapeutics' S-1 registration statement (File No. 333-296090) was declared effectiv
Jun 3, 2026
NEUTRAL
8-K
3/10
Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its Board of
May 28, 2026
BEARISH
8-K
6/10
BrainStorm Cell Therapeutics reported Q1 2026 results with a net loss of $2.1M ($0.19 per share), na
May 15, 2026
BULLISH
8-K
8/10
BrainStorm Cell Therapeutics reported a narrower-than-expected net loss for full-year 2025, with EPS
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jul 2024): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.29 | $-0.29 | $-0.29 | 14.7% | -20.8% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.21 | $-0.21 | $-0.21 | -10.5% | -10.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.07 | $-1.07 | $-1.07 | 3.6% | +29.1% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.86 | $-0.86 | $-0.86 | 19.6% | +16.5% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.290 | |
| 7d ago | $-0.240 | -0.050 |
| 30d ago | $-0.240 | -0.050 |
| 60d ago | $-0.240 | -0.050 |
| 90d ago | $-0.260 | -0.030 |
2 analyst firms have rated this stock: 2 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jul 11, 2024 | Maxim Group | UPGRADE | Hold | Buy |
| Sep 28, 2023 | Maxim Group | DOWNGRADE | Buy | Hold |
| Mar 31, 2023 | Maxim Group | MAINTAIN | — | Buy |
| Feb 5, 2021 | Maxim Group | UPGRADE | Hold | Buy |
| May 15, 2018 | HC Wainwright & Co. | INITIATE | — | Buy |
| Aug 17, 2017 | Maxim Group | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
BCLI Q1 2026 Earnings Scheduled — 2026-05-13
Mar 30, 2026
earnings_calendar
BCLI Q4 2025 Earnings After Market Close — 2026-03-30